Top-Rated StocksTop-RatedNASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis $27.65 +0.62 (+2.29%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$27.18 -0.47 (-1.70%) As of 10/15/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amylyx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$27.45▼$28.3450-Day Range$21.43▼$39.6652-Week Range$10.83▼$41.14Volume882,545 shsAverage Volume1.40 million shsMarket Capitalization$3.08 billionP/E RatioN/ADividend YieldN/APrice Target$40.71Consensus RatingBuy Company Overview Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company is advancing a pipeline of investigational therapies across endocrine conditions and neurodegenerative diseases, including avexitide for post-bariatric hypoglycemia, AMX0035 for Wolfram syndrome, AMX0114 for amyotrophic lateral sclerosis, and AMX0318 for post-bariatric hypoglycemia and other rare diseases. Founded in 2013 by Joshua Cohen and Justin Klee, Amylyx is headquartered in Cambridge, Massachusetts. Cohen and Klee have served as the company’s co-chief executive officers and have led its efforts to advance therapies for diseases with high unmet needs. Read More Amylyx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreAMLX MarketRank™: 3.68362396748 of 5 starsAmylyx Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat, and ranked 259th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAmylyx Pharmaceuticals has a consensus price target of $40.71, representing about 47.2% upside from its current price of $27.65.Amount of Analyst CoverageAmylyx Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amylyx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($1.48) to ($1.40) per share.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 9.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amylyx Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.76% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 9.16.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently decreased by 6.26%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.91 News SentimentAmylyx Pharmaceuticals has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Amylyx Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,815,257.00 in company stock.Percentage Held by Insiders10.90% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amylyx Pharmaceuticals' insider trading history. Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMLX Stock News HeadlinesAmylyx Pharmaceuticals (NASDAQ:AMLX) Stock: Insider George Milne, Jr. Sells 30,000 SharesOctober 9, 2026 | americanbankingnews.comAmylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual MeetingOctober 6, 2026 | marketscreener.comMYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold. | American Alternative (Ad)Analysts Offer Insights on Healthcare Companies: Cooper Co (COO), Amylyx Pharmaceuticals Inc (AMLX) and CervoMed (CRVO)October 2, 2026 | theglobeandmail.comAmylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic ForumSeptember 23, 2026 | marketscreener.comMAmylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comAmylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?August 21, 2026 | insidermonkey.comAmylyx Pharmaceuticals Readies for Pivotal LUCIDITY DataAugust 20, 2026 | theglobeandmail.comSee More Headlines AMLX Stock Analysis - Frequently Asked Questions How have AMLX shares performed this year? Amylyx Pharmaceuticals' stock was trading at $12.08 at the beginning of 2026. Since then, AMLX shares have increased by 128.9% and is now trading at $27.65. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.03. Read the conference call transcript. When did Amylyx Pharmaceuticals IPO? Amylyx Pharmaceuticals (AMLX) raised $190 million in an IPO on Thursday, January 6th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share. Who are Amylyx Pharmaceuticals' major shareholders? Amylyx Pharmaceuticals' top institutional shareholders include GAMMA Investing LLC. Insiders that own company stock include Joshua B Cohen, Justin B Klee, George M Milne Jr, Camille L Bedrosian, James M Frates, Patrick D Yeramian, Gina Mazzariello, Karen Firestone, Bernhardt G Zeiher and Daphne Quimi. View institutional ownership trends. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amylyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amylyx Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Palantir Technologies (PLTR), Broadcom (AVGO) and Salesforce (CRM). Company Calendar Last Earnings8/06/2026Today10/15/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 AMLX's financial health is in the Green zone, according to TradeSmith. AMLX has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AMLX CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees136Year Founded2013Price Target and Rating Average Price Target for Amylyx Pharmaceuticals$40.71 High Price Target$57.00 Low Price Target$19.00 Potential Upside/Downside+47.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$144.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-52.92% Return on Assets-48.53% Debt Debt-to-Equity RatioN/A Current Ratio12.12 Quick Ratio12.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.78 per share Price / Book9.95Miscellaneous Outstanding Shares111,423,000Free Float99,278,000Market Cap$3.08 billion OptionableOptionable Beta-0.10 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:AMLX) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersWall Street’s giving up on this trade. I’m not.Major banks have slashed their gold price targets - Morgan Stanley to $4450, JPMorgan to $4500 - after predict...Traders Agency | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMy biggest prediction yet?!James Altucher called Facebook's rise past 100 billion dollars in 2007 and Apple's run to a trillion years lat...Paradigm Press | SponsoredA simple options strategy that changed one trader's pathIan Cooper went from a financially stressed, struggling journalist to a trader who discovered a repeatable opt...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
